HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.

Abstract
Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.
AuthorsPhillip Parente, Francis Parnis, Howard Gurney
JournalAsia-Pacific journal of clinical oncology (Asia Pac J Clin Oncol) Vol. 10 Issue 3 Pg. 205-15 (Sep 2014) ISSN: 1743-7563 [Electronic] Australia
PMID24750803 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2014 Wiley Publishing Asia Pty Ltd.
Chemical References
  • Androstenes
  • Cancer Vaccines
  • Taxoids
  • Tissue Extracts
  • Docetaxel
  • cabazitaxel
  • sipuleucel-T
  • Abiraterone Acetate
  • Radium
Topics
  • Abiraterone Acetate
  • Androstenes (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Cancer Vaccines (administration & dosage)
  • Docetaxel
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant (drug therapy, radiotherapy, therapy)
  • Radium (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Taxoids (administration & dosage)
  • Tissue Extracts (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: